the broad range of clinical manifestations that interfere with patients' lives. The survey allowed us to quantify the rate of disease progression and the positive effects of ERT on patients' quality of life, fatigue, and participation in daily life. Furthermore, it showed, for the fi rst time, that survival is reduced in adults with Pompe disease and improved by ERT. Our results show that a patient survey can serve as a valuable and reliable tool for obtaining quantifi able information on the natural course of a rare disease, and on the effects of therapy in a large cohort. Most importantly, by working with patient-reported outcomes, the survey provides the data that are truly relevant to the patient and complementary to clinical datasets.
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